<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04935411</url>
  </required_header>
  <id_info>
    <org_study_id>CRTH258ARU01</org_study_id>
    <nct_id>NCT04935411</nct_id>
  </id_info>
  <brief_title>Russian Registry of Patients With nAMD</brief_title>
  <official_title>Russian Registry of Patients With Neovascular Age-Related Macular Degeneration (nAMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A three-year, non-randomized, observational, multicenter prospective nAMD study - patient&#xD;
      registry.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The registry is a structured system which uses observational study methods for systematic&#xD;
      collection of data on health condition in the specific patient population.&#xD;
&#xD;
      Real world clinical practice data will be collected. Patients will not undergo any additional&#xD;
      examinations or procedures that are outside of the standard clinical practice&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients by gender</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of patients by gender to be provided</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Age at the diagnosis</measure>
    <time_frame>Baseline</time_frame>
    <description>Age at the diagnosis to be provided</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with comorbidities and concomitant procedures and medications</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of patients with systemic and ophthalmic comorbidities and percentage of patients with concomitant procedures and medications to be provided</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patients with unilateral or bilateral disease</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of patients with unilateral or bilateral disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time from diagnosis to entry to the registry</measure>
    <time_frame>Baseline</time_frame>
    <description>Mean time from diagnosis to entry to the registry to be presented</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Social Characteristics (Working and Disability status)</measure>
    <time_frame>Baseline</time_frame>
    <description>Working status (number of patients that work/does not work, with age-related pension, disability pension).&#xD;
Disability status (number of patients established/not established, removed, disability group, whether AMD is the main reason for disability)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Baseline, up to 2 years</time_frame>
    <description>Changes in visual acuity assessed by Sivcev-Golovin's table (The table consists of two parts with 12 rows each, representing visual acuity values between 0.1 and 2.0.) or Snellen equivalent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of edema and/or neuroepithelium detachment and/or pigment epithelium detachment</measure>
    <time_frame>Baseline, Up to 2 years</time_frame>
    <description>Presence of edema and/or neuroepithelium detachment and/or pigment epithelium detachment. (yes/no)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of macular atrophy</measure>
    <time_frame>Baseline, Up to 2 years</time_frame>
    <description>Presence of macular atrophy (with or without foveal involvement) (yes/no)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Central retinal thickness</measure>
    <time_frame>Baseline, Up to 2 years</time_frame>
    <description>Central retinal thickness to be measured with OCT (optical coherent tomography)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fluid type</measure>
    <time_frame>Baseline, Up to 2 years</time_frame>
    <description>Type of the fluid assessed by optical coherence tomography and defined as follows: intraretinal fluid (IRF), subretinal fluid (SRF), fluid under repinal pigment epithelium (sub-RPE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Indication for intravitreal anti-VEGF therapy</measure>
    <time_frame>Baseline, Up to 2 years</time_frame>
    <description>Indication for intravitreal anti-VEGF therapy to be collected</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type of prescribed therapy</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Type of prescribed therapy (anti-VEGF, PDT, laser coagulation, retinolamine, emoxipine, etc.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with prescription of anti-VEGF drugs</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Percentage of patients with prescription of anti-VEGF drugs to be collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from diagnosis to the therapy initiation</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Mean time from the diagnosis to the initiation of any therapy for nAMD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from diagnosis to anti-VEGF injection</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Mean time from the diagnosis to the first anti-VEGF injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visits per year</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of visits per year to be collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of anti-VEGF injections per year</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of anti-VEGF injections to be collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Optical coherence tomography (OCTs) done per year</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of OCTs done per year to be collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of treatment discontinuation</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Rate of treatment discontinuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for treatment discontinuation</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Reasons for treatment discontinuation</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Neovascular Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>nAMD patients</arm_group_label>
    <description>patients diagnosed with Neovascular Age-Related Macular Degeneration</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>nAMD</intervention_name>
    <description>patients diagnosed with Neovascular Age-Related Macular Degeneration</description>
    <arm_group_label>nAMD patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Neovascular Age-Related Macular Degeneration in Russia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; to 18 years&#xD;
&#xD;
          -  Male or female patients diagnosed with nAMD (with or without previous treatment for&#xD;
             nAMD including but not limited to PDT, laser coagulation, vitamins, retinolamine,&#xD;
             emoxipine, anti-VEGF therapy or any surgery for nAMD).&#xD;
&#xD;
          -  Willing and able to provide informed written consent personally or by legal proxy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient does not meet the inclusion criteria;&#xD;
&#xD;
          -  The patient is simultaneously participating in a different nAMD therapy study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neovascular Age-Related Macular Degeneration</keyword>
  <keyword>nAMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

